8-K: Philip Morris International Raises 2026 EPS Forecast

Philip Morris International Inc. announced an upward revision to its 2026 adjusted diluted EPS forecast and highlighted strong growth in smoke-free products at the Barclays Global Consumer Conference.

Summary

• Philip Morris International (PMI) is hosting a presentation at the Barclays Global Consumer Conference on September 8, 2026.
• The company has raised its 2026 adjusted diluted Earnings Per Share (EPS) forecast to a range of $8.35 to $8.50, representing 10.7% to 12.7% growth.
• This revised forecast includes a favorable currency impact of 24 cents.
• The Q3 2026 adjusted diluted EPS forecast is between $2.29 and $2.34, with a 1-cent favorable currency impact.
• IQOS is driving broad-based smoke-free growth, with Japan consumer offtake recovery meeting expectations and pricing confirmed for October.
• Strong multicategory growth is noted in international markets, including VEEV and ZYN.
• PMI is expanding its U.S. ZYN range and will transition 3mg and 6mg dry variants to 20 pouches/can in Q4.
• Combustibles continue to perform robustly as expected, particularly in markets with smoke-free product (SFP) bans or limited presence.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, indicating strong performance and an upward revision of financial guidance, though it also highlights ongoing risks inherent in the tobacco and nicotine industry.

Positives

• Raised 2026 adjusted diluted EPS forecast to $8.35 $8.50, indicating 10.7% to 12.7% growth.
• Strong multicategory growth in international markets, including VEEV and ZYN.
• IQOS performance in Japan is recovering in line with expectations.
• Continued robust performance from combustible products, as anticipated.
• Expansion of the U.S. ZYN range and portfolio alignment.

Negatives

• The filing acknowledges ongoing risks related to marketing and regulatory restrictions, excise tax increases, and health concerns.
• Potential for litigation related to tobacco and nicotine products remains a concern.
• Continued decline of tax-paid cigarettes is noted.
• Lost revenues due to counterfeiting, contraband, and cross-border purchases are a factor.

Risks

• Marketing and regulatory restrictions could reduce competitiveness and disrupt SFP commercialization.
• Excise tax increases and discriminatory tax structures pose a risk.
• Health concerns related to tobacco and nicotine products.
• Litigation related to tobacco/nicotine products and intellectual property rights.
• Intense competition and inability to anticipate changes in adult consumer preferences.
• Reliance on third-party suppliers and potential disruptions.
• Adverse global and country-specific economic, regulatory, and political developments.
• Geopolitical instability and the impact of conflicts, such as Russia's invasion of Ukraine.

Future Outlook

The company has raised its 2026 adjusted diluted EPS forecast to a range of $8.35 to $8.50, reflecting 10.7% to 12.7% growth, including a favorable currency impact of 24 cents. The Q3 2026 forecast is $2.29 to $2.34, with a 1-cent favorable currency impact. PMI anticipates continued robust performance from combustibles and expects IQOS to drive smoke-free growth.

Management Comments

• Jacek Olczak, Group CEO PMI, is presenting at the Barclays Global Consumer Conference.
• The company is 'Championing a Smoke-Free World'.

Industry Context

StockSavvy.ai notes that PMI's presentation aligns with the broader industry trend of transitioning towards reduced-risk or smoke-free products, while still acknowledging the continued, albeit declining, importance of traditional combustible products in certain markets.

Legal Proceedings

• Potential litigation related to tobacco and/or nicotine products and intellectual property rights.
• Potential excise tax increases and discriminatory tax structures.
• Potential governmental investigations.

Stakeholder Impact

• Shareholders: Positive impact from raised EPS guidance and strong performance in smoke-free and combustible segments.
• Consumers: Continued availability of IQOS and ZYN products, with potential changes in packaging for ZYN.
• Employees: Implied continued investment in R&D and commercialization of smoke-free products.
• Regulators: Ongoing engagement with evolving regulatory landscapes and potential for increased taxes and restrictions.

Next Steps

• October pricing for IQOS in Japan is confirmed.
• Transition of 3mg and 6mg dry ZYN variants to 20 pouches/can in Q4.
• Continued commercialization efforts for smoke-free products.

Key Dates

Recommendation

The raised EPS guidance and strong performance in key product categories are positive. However, the persistent and significant risks associated with the tobacco and nicotine industry, including regulatory pressures, litigation, and health concerns, warrant a cautious approach. While the transition to smoke-free products is progressing, the continued reliance on combustibles and the inherent risks suggest a 'hold' rating until further clarity on long-term regulatory outcomes and SFP market penetration is achieved.

Keywords

Smoke-Free Products, EPS Guidance, Consumer Conference, Philip Morris International, Barclays, IQOS, ZYN, VEEV